

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
3 November 2005 (03.11.2005)

PCT

(10) International Publication Number
WO 2005/103021 A1

(51) International Patent Classification⁷: **C07D 277/46**,
A61K 31/427, A61P 3/10

(21) International Application Number:
PCT/GB2005/050053

(22) International Filing Date: 19 April 2005 (19.04.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/564,171 21 April 2004 (21.04.2004) US
60/601,077 12 August 2004 (12.08.2004) US

(71) Applicant (for all designated States except US): **PRO-
SIDION LIMITED** [GB/GB]; Windrush Court Watling-
ton Road, Oxford Oxfordshire OX4 6LT (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **FYFE, Matthew**
[GB/GB]; Windrush Court Watlington Road, Oxford
Oxfordshire OX4 6LT (GB).

(74) Agent: **BLAKEY, Alison**; Prosidion Limited, Windrush
Court Watlington Road, Oxford Oxfordshire OX4 6LT
(GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS



(57) Abstract: Compounds of Formula (I) or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.

WO 2005/103021 A1

TITLE OF THE INVENTION

TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS

5 BACKGROUND OF THE INVENTION

The present invention is directed to tri(cyclo) substituted amide compounds. In particular, the present invention is directed to amide compounds substituted i) at the carbonyl carbon with an ethyl/ethenyl attached to a phenyl ring and a carbocyclic ring, and ii) at the amino with a fluoro substituted thiazole ring, which are modulators of glucokinase and are useful in the prophylactic or therapeutic treatment of hyperglycemia and diabetes, particularly type II diabetes.


Glucokinase ("GK") is believed to be important in the body's regulation of its plasma glucose level. GK, found principally in the liver and pancreas, is one of four hexokinases that catalyze the initial metabolism of glucose. The GK pathway is saturated at higher glucose levels than the other hexokinase pathways (See R.L. Printz et al., *Annu. Rev. Nutr.*, 13:463-496 (1993)). GK is critical to maintaining the glucose balance in mammals. Animals that do not express GK die soon after birth with diabetes, while animals that overexpress GK have improved glucose tolerance. Activation of GK can lead to hyperinsulinemic hypoglycemia. (See, for example, H.B.T. Christesen et al., *Diabetes*, 51:1240-1246 (2002)). Additionally, type II maturity-onset diabetes of the young is caused by the loss of function mutations in the GK gene, suggesting that GK operates as a glucose sensor in humans (Y. Liang et al., *Biochem. J.* 309:167-173 (1995)). Thus, compounds that activate GK increase the sensitivity of the GK sensory system and would be useful in the treatment of hyperglycemia – particularly the hyperglycemia associated with type II diabetes. It is therefore desirable to provide novel compounds that activate GK to treat diabetes.

International Patent Publication No. WO2001/044216 and U.S. Patent No. 6,353,111 describe (*E*)-2,3-disubstituted-*N*-heteroarylacrylamides as GK activators. International Patent Publication No. WO2002/014312 and U.S. Patent Nos. 6,369,232, 6,388,088 and 6,441,180 describe tetrazolylphenylacetamide GK activators. International Patent Publication No. WO2000/058293, European Patent Application No. EP 1169312 and U.S. Patent No. 6,320,050 describe arylcycloalkylpropionamide GK activators. International Patent Publication No. WO2002/008209 and U.S. Patent No. 6,486,184 describe alpha-acyl and alpha-heteroatom-substituted benzene acetamide GK activators as anti-diabetic agents. International Patent Publication No. WO2001/083478 describes hydantoin-containing GK activators. International Patent Publication No. WO2001/083465 and U.S. Patent No. 6,388,071 describe alkynylphenyl heteroaromatic GK activators. International Patent Publication No. WO2001/085707 and U.S. Patent No. 6,489,485 describe para-amine substituted phenylamide GK activators. International Patent Publication No. WO2002/046173 and U.S. Patent Nos. 6,433,188, 6,441,184 and 6,448,399 describe fused heteroaromatic GK activators. International Patent Publication No. WO2002/048106 and U.S. Patent No. 6,482,951 describe isoindolin-1-one GK activators. International Patent Publication No.

WO2001/085706 describes substituted phenylacetamide GK activators for treating type II diabetes. U.S. Patent No. 6,384,220 describes para-aryl or heteroaryl substituted phenyl GK activators. French Patent No. 2,834,295 describes methods for the purification and crystal structure of human GK. International Patent Publication No. WO2003/095438 describes *N*-heteroaryl phenylacetamides and related compounds as GK activators for the treatment of type II diabetes. U.S. Patent No. 6,610,846 describes the preparation of cycloalkylheteroaryl propionamides as GK activators. International Patent Publication No. WO2003/000262 describes vinyl phenyl GK activators. International Patent Publication No. WO2003/000267 describes aminonicotinate derivatives as GK modulators. International Patent Publication No. WO2003/015774 describes compounds as GK modulators. International Patent Publication No. WO2003/047626 describes the use of a GK activator in combination with a glucagon antagonist for treating type II diabetes. International Patent Publication No. WO2003/055482 describes amide derivatives as GK activators. International Patent Publication No. WO2003/080585 describes aminobenzamide derivatives with GK activity for the treatment of diabetes and obesity. International Patent Publication No. WO2003/097824 describes human liver GK crystals and their used for structure-based drug design. International Patent Publication No. WO2004/002481 discloses arylcarbonyl derivatives as GK activators. International Patent Publication Nos. WO2004/072031 and WO2004/072066 (published after the priority date of the present application) discloses various tri(cyclo) substituted amide compounds which are modulators of glucokinase.

SUMMARY OF THE INVENTION

Compounds represented by Formula (I):




(I)

or pharmaceutically acceptable salts thereof, are useful in the prophylactic or therapeutic treatment of hyperglycemia and diabetes, particularly type II diabetes.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

V is $(CH_2)_k$ where one CH_2 group may optionally be replaced by $CH(OH)$, $C=O$, $C=NOH$,
 5 $C=NOCH_3$, CHX , CXX^1 , $CH(OCH_3)$, $CH(OCOCH_3)$, $CH(C_{1-4}alkyl)$, or $C(OH)(C_{1-4}alkyl)$;

X and X^1 are independently selected from fluoro and chloro;

R^1 and R^2 are independently selected from hydrogen, halogen, hydroxy, amino, cyano, nitro,
 SR^3 , SOR^3 , SO_2R^3 , $SO_2NR^4R^5$, $NHSO_2R^3$, or a $C_{1-4}alkyl$, $C_{2-4}alkenyl$, $C_{2-4}alkynyl$, $C_{1-4}alkoxy$, or
 10 heteroaryl group, wherein any group is optionally substituted with 1 to 5 substituents independently
 selected from halogen, cyano, nitro, hydroxy, $C_{1-2}alkoxy$, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$, $C_{1-2}alkyl$,
 CF_nH_{3-n} , aryl, heteroaryl, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, SCH_3 , $SOCH_3$, SO_2CH_3 , and $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$;

R^3 is a $C_{1-4}alkyl$ group, $C_{3-7}cycloalkyl$ group, aryl group, heteroaryl group, or 4- to 7-
 membered heterocyclic group, wherein any group is optionally substituted with 1 to 5 substituents
 15 independently selected from halogen, cyano, nitro, hydroxy, $C_{1-2}alkoxy$, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$,
 $C_{1-2}alkyl$, $C_{3-7}cycloalkyl$, 4- to 7-membered heterocyclic ring, CF_nH_{3-n} , aryl, heteroaryl, $COC_{1-2}alkyl$,
 $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, $SOCH_3$, SO_2CH_3 , and $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$;

R^4 and R^5 are independently hydrogen, or a $C_{1-4}alkyl$ group, $C_{3-7}cycloalkyl$ group, aryl group,
 heteroaryl group, or 4- to 7-membered heterocyclic group, wherein any group is optionally
 20 substituted with 1 to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, $C_{1-2}alkoxy$,
 $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$, $C_{1-2}alkyl$, $C_{3-7}cycloalkyl$, 4- to 7-membered heterocyclic ring,
 CF_nH_{3-n} , aryl, heteroaryl, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, $SOCH_3$, SO_2CH_3 , and $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$;

or R^4 and R^5 together form a 4- to 8-membered heterocyclic ring which is optionally
 25 substituted with 1 or 2 substituents independently selected from $C_{1-2}alkyl$ and hydroxy;

k is an integer from 2 to 7;

m is 0 or 1;


n is 1, 2 or 3; and

the dotted line together with the solid line forms an optional double bond, and Δ indicates that
 30 the double bond has the (E)-configuration.

If the dotted line together with the solid line forms a single bond, the carbon atom linking the
 aryl ring and $-HC\equiv V$ -containing sidechain to the amide carbonyl carbon, i.e. the carbon atom
 labelled with "*", is a chiral centre. Accordingly, at this centre, the compound may be present either

as a racemate or as a single enantiomer in the (*R*)- or (*S*)-configuration. The (*R*)-enantiomers are preferred. The carbon atom labelled with “#” may also be chiral. Accordingly, at this centre, the compound may be present either as a racemate or as a single enantiomer in the (*R*)- or (*S*)-configuration. The (*R*)-enantiomers are preferred when the dotted line together with the solid line represents a single bond. When the dotted line together with the solid line forms a double bond, the (*S*)-enantiomers are preferred.

In a further aspect, the present invention is directed to a compound represented by Formula (Ia):




(Ia)

or a pharmaceutically acceptable salt thereof, wherein V, R¹, R², m and Δ are as defined above in Formula (I).

In another embodiment, the present invention is directed to a compound represented by Formula (Ia), or a pharmaceutically acceptable salt thereof, wherein the group formed by –HC< and >V represents oxocycloalkyl or hydroxycycloalkyl, e.g. 3-oxocyclopentyl particularly (*R*)-3-oxocyclopentyl, 4-oxocyclohexyl or 3-hydroxycyclopentyl, especially (*R*)-3-oxocyclopentyl.

In a further and preferred aspect, the present invention is directed to a compound represented by Formula (Ib):



(Ib)

or a pharmaceutically acceptable salt thereof, wherein V, R¹, R² and m are as defined above in Formula (I).

In an embodiment of this preferred aspect, the present invention is directed to a compound represented by Formula (Ib), or a pharmaceutically acceptable salt thereof, wherein the group formed by –HC< and >V represents oxocycloalkyl or hydroxycycloalkyl, e.g. 3-oxocyclopentyl particularly (*R*)-3-oxocyclopentyl, 4-oxocyclohexyl or 3-hydroxycyclopentyl, especially (*R*)-3-oxocyclopentyl.

The molecular weight of the compounds of Formula (I) is preferably less than 800, more preferably less than 600, most preferably less than 500.

In the present invention, R^1 and R^2 are preferably not both hydrogen.

In the present invention, R^1 is preferably CF_3 , SOR^3 , SO_2R^3 , $SO_2NR^4R^5$, $NHSO_2R^3$, or triazolyl; more preferably SOR^3 , SO_2R^3 , or $SO_2NR^4R^5$; most preferably SO_2R^3 or $SO_2NR^4R^5$, especially SO_2R^3 .

In particular R^1 is SO_2C_{3-4} cycloalkyl, especially SO_2 cyclopropyl.

In the present invention, R^2 is preferably hydrogen, chloro, fluoro, or trifluoromethyl; more preferably hydrogen or chloro.

In the present invention, R^3 is preferably C_{1-3} alkyl or C_{3-4} cycloalkyl, more preferably C_{3-4} cycloalkyl, especially cyclopropyl.

In the present invention, R^4 and R^5 are preferably independently hydrogen or C_{1-4} alkyl, e.g. one of R^4 and R^5 is hydrogen and the other is ethyl, or combine to form a 4- to 8-membered heterocyclic ring. R^4 and R^5 are preferably not both hydrogen.

In the present invention, m is preferably 0.

In the present invention V is preferably $(CH_2)_k$ where one CH_2 group is replaced by $CH(OH)$ or $C=O$.

In the present invention, k is preferably 4 or 5.

Specific compounds of the invention which may be mentioned are:

2(R)-2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide;

2(R)-2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide;

2(R)-2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-((S)-3-oxocyclopentyl)acrylamide;

(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(4-oxocyclohexyl)acrylamide;

(E)-N-(5-Fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)-2-(4-methanesulfonylphenyl)acrylamide;

2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide;

2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide;

2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-oxocyclopentyl)propionamide;

2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide;

2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

5 2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide;

2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide; and

10 2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

or a pharmaceutically acceptable salt of any one thereof.

While the preferred groups for each variable have generally been listed above separately for each variable, preferred compounds of this invention include those in which several or each variable in Formula (I) is selected from the preferred, more preferred, most preferred, especially or
15 particularly listed groups for each variable. Therefore, this invention is intended to include all combinations of preferred, more preferred, most preferred, especially and particularly listed groups.

As used herein, unless stated otherwise, "alkyl" as well as other groups having the prefix "alk" such as, for example, alkoxy, alkenyl, alkynyl, and the like, means carbon chains which may be linear or branched or combinations thereof. Examples of alkyl groups include methyl, ethyl,
20 propyl, isopropyl, butyl, *sec*- and *tert*-butyl, pentyl, hexyl, heptyl and the like. "Alkenyl", "alkynyl" and other like terms include carbon chains having at least one unsaturated carbon-carbon bond.

As used herein, for example, "C₀₋₄alkyl" is used to mean an alkyl having 0-4 carbons – that is, 0, 1, 2, 3, or 4 carbons in a straight or branched configuration. An alkyl having no carbon is hydrogen when the alkyl is a terminal group. An alkyl having no carbon is a direct bond when the
25 alkyl is a bridging (connecting) group.

The terms "cycloalkyl" and "carbocyclic ring" mean carbocycles containing no heteroatoms, and includes monocyclic saturated C₃₋₇carbocycles. Examples of cycloalkyl and carbocyclic rings include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl and the like.

The term "halogen" includes fluorine, chlorine, bromine, and iodine atoms.

30 The term "aryl" includes, for example, phenyl and naphthyl, preferably phenyl.

Unless otherwise stated, the term "heterocyclic ring" includes 4- to 8-membered saturated rings containing one or two heteroatoms selected from oxygen, sulfur and nitrogen. The heteroatoms are not directly attached to one another. Examples of heterocyclic rings include oxetane, tetrahydrofuran, tetrahydropyran, oxepane, oxocane, thietane, tetrahydrothiophene,
35 tetrahydrothiopyran, thiopane, thiocane, azetidine, pyrrolidine, piperidine, azepane, azocane, [1,3]dioxane, oxazolidine, piperazine, and the like. Other examples of heterocyclic rings include the oxidised forms of the sulfur-containing rings. Thus, tetrahydrothiophene 1-oxide,

tetrahydrothiophene 1,1-dioxide, tetrahydrothiopyran 1-oxide, and tetrahydrothiopyran 1,1-dioxide are also considered to be heterocyclic rings.

Unless otherwise stated, the term "heteroaryl" includes 5- or 6-membered heteroaryl rings containing 1–4 heteroatoms selected from oxygen, sulfur and nitrogen. Examples of such heteroaryl rings are furyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl.

The above formulae are shown without a definitive stereochemistry at certain positions. The present invention includes all stereoisomers (e.g. geometric isomers, optical isomers, diastereoisomers, etc.) and pharmaceutically acceptable salts thereof, except where specifically drawn or stated otherwise. Further, mixtures of stereoisomers as well as isolated specific stereoisomers are also included, except where specifically drawn or stated otherwise. During the course of the synthetic procedures used to prepare such compounds, or in using racemization or epimerization procedures known to those skilled in the art, the products of such procedures can be a mixture of stereoisomers. When a tautomer of the compound of the above formulae exists, the present invention includes any possible tautomers and pharmaceutically acceptable salts thereof, and mixtures thereof, except where specifically drawn or stated otherwise. When the compound of the above formulae and pharmaceutically acceptable salts thereof exist in the form of solvates or polymorphic forms, the present invention includes any possible solvates and polymorphic forms. The type of a solvent that forms the solvate is not particularly limited so long as the solvent is pharmacologically acceptable. For example, water, ethanol, propanol, acetone or the like can be used.

Since the compounds of Formula (I) are intended for pharmaceutical use they are preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure, at least 95% pure and especially at least 98% pure (% are on a weight for weight basis).

The invention also encompasses a pharmaceutical composition that is comprised of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

Preferably the composition is comprised of a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Moreover, within this embodiment, the invention encompasses a pharmaceutical composition for the prophylaxis or treatment of hyperglycemia and diabetes, particularly type II diabetes, by the activation of GK, comprising a pharmaceutically acceptable carrier and a non-toxic therapeutically effective amount of compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof as a pharmaceutical.

The compounds and compositions of the present invention are effective for treating hyperglycemia and diabetes, particularly type II diabetes, in mammals such as, for example, humans.

The invention also provides a method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a
5 compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The invention also provides a method of prophylactic or therapeutic treatment of hyperglycemia or diabetes, particularly type II diabetes, comprising a step of administering an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The invention also provides a method of prevention of diabetes, particularly type II diabetes,
10 in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as a GK activator.

15 The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the prophylactic or therapeutic treatment of hyperglycemia or diabetes, particularly type II diabetes.

The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the prevention of diabetes, particularly type II diabetes, in a human
20 demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance.

The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the activation of GK.

The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prophylactic or therapeutic
25 treatment of hyperglycemia or diabetes, particularly type II diabetes.

The invention also provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the prevention of diabetes, particularly type II diabetes, in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance.

30 The compounds and compositions of the present invention may be optionally employed in combination with one or more other anti-diabetic agents or anti-hyperglycemic agents, which include, for example, sulfonylureas (e.g. glyburide, glimepiride, glipiride, glipizide, chlorpropamide, gliclazide, glisoxepid, acetohexamide, glibornuride, tolbutamide, tolazamide, carbutamide, gliquidone, glyhexamide, phenbutamide, tolcyclamide, etc.), biguanides (e.g. metformin,
35 phenformin, buformin, etc.), glucagon antagonists (e.g. a peptide or non-peptide glucagon antagonist), glucosidase inhibitors (e.g. acarbose, miglitol, etc.), insulin secretagogues, insulin sensitizers (e.g. troglitazone, rosiglitazone, pioglitazone, etc.) and the like; or anti-obesity agents (e.g. sibutramine, orlistat, etc.) and the like. The compounds and compositions of the present invention

and the other anti-diabetic agents or anti-hyperglycemic agents may be administered simultaneously, sequentially or separately.

The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids. When the compound of the present invention is acidic, its
5 corresponding salt can be conveniently prepared from pharmaceutically acceptable non-toxic bases, including inorganic bases and organic bases. Salts derived from such inorganic bases include aluminum, ammonium, calcium, cupric, cuprous, ferric, ferrous, lithium, magnesium, manganic, manganous, potassium, sodium, zinc and the like salts. Particularly preferred are the ammonium, calcium, magnesium, potassium and sodium salts. Salts derived from pharmaceutically acceptable
10 organic non-toxic bases include salts of primary, secondary, and tertiary amines, as well as cyclic amines and substituted amines such as naturally occurring and synthetic amines. Other pharmaceutically acceptable organic non-toxic bases from which salts can be formed include, for example, arginine, betaine, caffeine, choline, N',N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine,
15 N-ethylpiperidine, glucamine, glucosamine, histidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.

When the compound of the present invention is basic, its corresponding salts can be conveniently prepared from pharmaceutically acceptable non-toxic acids, including inorganic and
20 organic acids. Such acids include, for example, acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pantoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, methanesulfonic, and tartaric acids.

The pharmaceutical compositions of the present invention comprise a compound of Formula (I), or a pharmaceutically acceptable salt thereof, as an active ingredient, a pharmaceutically acceptable carrier and optionally other therapeutic ingredients or adjuvants. The compositions include compositions suitable for oral, rectal, topical, and parenteral (including subcutaneous, intramuscular, and intravenous) administration, as well as administration through inhaling, although
30 the most suitable route in any given case will depend on the particular host, and nature and severity of the conditions for which the active ingredient is being administered. The pharmaceutical compositions may be conveniently presented in unit dosage form and prepared by any of the methods well known in the art of pharmacy.

The pharmaceutical compositions according to the invention are preferably adapted for oral
35 administration.

In practice, the compounds of Formula (I), or pharmaceutically acceptable salts thereof, can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of

forms depending on the form of preparation desired for administration, e.g. oral or parenteral (including intravenous). Thus, the pharmaceutical compositions of the present invention can be presented as discrete units suitable for oral administration such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient. Further, the compositions can be presented as a powder, as granules, as a solution, as a suspension in an aqueous liquid, as a non-aqueous liquid, as an oil-in-water emulsion, or as a water-in-oil liquid emulsion. In addition to the common dosage forms set out above, the compound of Formula (I), or a pharmaceutically acceptable salt thereof, may also be administered by controlled release means and/or delivery devices. The compositions may be prepared by any of the methods of pharmacy. In general, such methods include a step of bringing into association the active ingredient with the carrier that constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both. The product can then be conveniently shaped into the desired presentation.

Thus, the pharmaceutical compositions of this invention may include a pharmaceutically acceptable carrier and a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The compounds of Formula (I), or pharmaceutically acceptable salts thereof, can also be included in pharmaceutical compositions in combination with one or more other therapeutically active compounds.

The pharmaceutical compositions of this invention include a pharmaceutically acceptable liposomal formulation containing a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

The pharmaceutical carrier employed can be, for example, a solid, liquid, or gas. Examples of solid carriers include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. Examples of liquid carriers are sugar syrup, peanut oil, olive oil, and water. Examples of gaseous carriers include carbon dioxide and nitrogen.

In preparing the compositions for oral dosage form, any convenient pharmaceutical media may be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents, and the like may be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like may be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets may be coated by standard aqueous or nonaqueous techniques.

A tablet containing the composition of this invention may be prepared by compression or molding, optionally with one or more accessory ingredients or adjuvants. Compressed tablets may be prepared by compressing, in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent or other such excipient. These excipients may be, for example, inert diluents such

as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay
5 disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer time. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be used.

In hard gelatin capsules, the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. In soft gelatin capsules, the active
10 ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Each tablet preferably contains from about 0.05mg to about 5g of the active ingredient and each cachet or capsule preferably containing from about 0.05mg to about 5g of the active ingredient.

For example, a formulation intended for the oral administration to humans may contain from
15 about 0.5mg to about 5g of active agent, compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95 percent of the total composition. Unit dosage forms will generally contain between from about 1mg to about 2g of the active ingredient, typically 25mg, 50mg, 100mg, 200mg, 300mg, 400mg, 500mg, 600mg, 800mg, or 1000mg.

Pharmaceutical compositions of the present invention suitable for parenteral administration
20 may be prepared as solutions or suspensions of the active compounds in water. A suitable surfactant can be included such as, for example, hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Further, a preservative can be included to prevent the detrimental growth of microorganisms.

Pharmaceutical compositions of the present invention suitable for injectable use include
25 sterile aqueous solutions or dispersions. Furthermore, the compositions can be in the form of sterile powders for the extemporaneous preparation of such sterile injectable solutions or dispersions. In all cases, the final injectable form must be sterile and must be effectively fluid for easy syringability. The pharmaceutical compositions must be stable under the conditions of manufacture and storage; thus, preferably should be preserved against the contaminating action of microorganisms such as
30 bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), vegetable oils, and suitable mixtures thereof.

Pharmaceutical compositions of the present invention can be in a form suitable for topical
35 use such as, for example, an aerosol, cream, ointment, lotion, dusting powder, or the like. Further, the compositions can be in a form suitable for use in transdermal devices. These formulations may be prepared, utilizing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, via conventional processing methods. As an example, a cream or ointment is prepared by admixing

hydrophilic material and water, together with about 5wt% to about 10wt% of the compound, to produce a cream or ointment having a desired consistency.

Pharmaceutical compositions of this invention can be in a form suitable for rectal administration wherein the carrier is a solid. It is preferable that the mixture forms unit dose suppositories. Suitable carriers include cocoa butter and other materials commonly used in the art. The suppositories may be conveniently formed by first admixing the composition with the softened or melted carrier(s) followed by chilling and shaping in molds.

Pharmaceutical compositions of this invention can be in a form suitable for inhaled administration. Such administration can be in forms and utilizing carriers described in, for example, Particulate Interactions in Dry Powder Formulations for Inhalation, Xian Zeng et al, 2000, Taylor and Francis; Pharmaceutical Inhalation Aerosol Technology, Anthony Hickey, 1992, Marcel Dekker; and Respiratory Drug Delivery, 1990, Editor: P.R. Byron, CRC Press.

In addition to the aforementioned carrier ingredients, the pharmaceutical compositions described above may include, as appropriate, one or more additional carrier ingredients such as diluents, buffers, flavoring agents, binders, surface-active agents, thickeners, lubricants, preservatives (including anti-oxidants) and the like. Furthermore, other adjuvants can be included to render the formulation isotonic with the blood of the intended recipient. Compositions containing a compound of Formula (I), or a pharmaceutically acceptable salt thereof, may also be prepared in powder or liquid concentrate form.


Generally, dosage levels of the order of from about 0.01mg/kg to about 150mg/kg of body weight per day are useful in the treatment of the above-indicated conditions, or alternatively about 0.5mg to about 10g per patient per day. For example, diabetes may be effectively treated by the administration of from about 0.01 to 100mg of the compound per kilogram of body weight per day, or alternatively about 0.5mg to about 7g per patient per day.

It is understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the disease in the particular diabetic patient undergoing therapy. Further, it is understood that the compounds and salts thereof of this invention can be administered at subtherapeutic levels prophylactically in anticipation of a hyperglycemic condition.

The compounds of Formula (I) may exhibit advantageous properties compared to known glucokinase activators, e.g. as illustrated in the assays described herein. In particular compounds of the invention may exhibit improved values for K_m , V_{max} , EC_{50} , maximum activation (glucose concentration = 5mM), and/or maximum blood glucose reduction on basal blood glucose levels (e.g. in C57BL/6J mice), or other advantageous pharmacological properties, compared to known GK activators

In accordance with this invention, the compounds of Formula (Ia) can be prepared following the protocol illustrated in **Scheme 1** below:

SCHEME 1



5 wherein V, R¹, R², m and Δ are as described above, and R¹¹ is C₁₋₄alkyl.


The aldehydes **II** and phenylacetic esters **III** are commercially available or are readily prepared using known techniques. The α-carbanion of the phenylacetic ester **III** (R¹¹ = C₁₋₄alkyl), generated at -78°C in, for example, tetrahydrofuran, by a strong base, e.g. lithium diisopropylamide, may be condensed with **II** to give an α,β-unsaturated ester (T. Severin et al. *Chem. Ber.* **1985**, *118*, 4760–
 10 4773) that may be saponified using, for example, sodium hydroxide (W. L. Corbett et al., WO2001/44216), to produce **IV**. If necessary, any functional groups within the intermediate compounds, e.g. oxo or hydroxy groups in the compounds of formula **II**, may be protected and the protecting groups removed using conventional means. For example oxo groups may be protected as ketals and hydroxy groups as ethers, e.g. methoxymethyl (MOM) ethers.

15 The α,β-unsaturated carboxylic acids **IV** may be condensed with 2-amino-5-fluorothiazole **V**, or a salt thereof e.g. the hydrochloride salt, which may be prepared as described in the examples, using a variety of coupling conditions, e.g. polymer supported carbodiimide-1-hydroxybenzotriazole in *N,N*-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdf and available from Argonaut

20 Technologies, Inc., Foster City, California), to give (Ia).

In accordance with this invention, the compounds of Formula (Ib) can be prepared following the protocol illustrated in **Scheme 2** below:

SCHEME 2



wherein V, R¹, R² and m are as described above, Y is CO₂R¹² wherein R¹² is hydrogen, C₁₋₄alkyl or benzyl; and X is chloro, bromo, iodo, or -OSO₂R¹³, wherein R¹³ is C₁₋₄alkyl, optionally substituted with one or more fluorines, or optionally substituted aryl.

The halides and sulfonate esters VI and the phenylacetic acids and esters VII are commercially available or are readily prepared using known techniques, for example as described in International Patent Publication Nos. WO2000/058293, WO2001/044216 and WO2003/095438. These alkylating agents may be reacted with the dianions of the phenylacetic acids VII, generated at -78°C in tetrahydrofuran with ≥2 equivalents of a strong base, such as lithium diisopropylamide, to generate VIII directly (F. T. Bizzarro et al., WO2000/58293). Alternatively, the α-carbanion of phenylacetic ester VII, generated at -78°C in tetrahydrofuran by a strong base, such as lithium bis(trimethylsilyl)amide (L. Snyder et al., *J. Org. Chem.* **1994**, 59, 7033-7037), can be alkylated by VI to give α-substituted esters. Saponification of these esters, employing, for example, sodium hydroxide in aqueous methanol at 20°C to reflux, leads to the carboxylic acids VIII. If necessary, any functional groups within the intermediate compounds, e.g. oxo or hydroxy groups in the compounds of formula VI, may be protected and the protecting groups removed using conventional means. For example oxo groups may be protected as ketals and hydroxy groups as ethers, e.g. methoxymethyl (MOM) ethers.

The carboxylic acids VIII may be condensed with 2-amino-5-fluorothiazole V, or a salt thereof e.g. the hydrochloride salt, which may be prepared as described in the examples, using a variety of coupling conditions, e.g. polymer supported carbodiimide-1-hydroxybenzotriazole in *N,N*-dimethylformamide at 20°C (for representative procedures, see http://www.argotech.com/PDF/resins/ps_carbodiimide.pdf and available from Argonaut Technologies, Inc., Foster City, California), to give amides (Ib).

The compound of Formula (Ib) has an asymmetric carbon atom which interlinks the amide carbonyl carbon, the aryl ring, and the -HC=V containing sidechain. In accordance with this invention, the preferred stereoconfiguration at the asymmetric centre is (*R*).

If one desires to isolate the pure (*R*)- or (*S*)-stereoisomers of the compound of Formula (Ib), it is possible to resolve a racemic mixture of the chiral carboxylic acid precursor VIII by any conventional chemical means and then condense the enantiopure carboxylic acids with 2-amino-5-fluorothiazole V, or a salt thereof, using a reagent that causes negligible racemisation. By way of illustration, racemic VIII can be condensed with a chiral oxazolidinone derivative (see, for instance, F. T. Bizzarro et al. WO2000/58293) to generate a mixture of diastereoisomeric imides that are separable by any conventional method, e.g. column chromatography. Hydrolysis of the pure imides affords the stereopure (*R*)- and (*S*)-carboxylic acids that can then be condensed with 2-amino-5-fluorothiazole V, or a salt thereof, employing a reagent that minimises racemisation of the chiral centre, e.g. benzotriazol-1-yloxytris(pyrrolidino)phosphonium hexafluorophosphate (J. Coste et al. *Tetrahedron Lett.* **1990**, 31, 205-208), to furnish enantiopure (*R*)- or (*S*)-amides of Formula (Ib). Alternatively, a racemic mixture of amides of Formula (Ib) can be separated by means of chiral high

performance liquid chromatography employing a chiral stationary phase which can be purchased from, for example, Daicel Chemical Industries, Ltd, Tokyo, Japan.

Various functional groups present in the compounds of Formula (I) and intermediates for use in the preparation thereof may be produced by functional group conversions known to those skilled in the art. For example in the compounds of formula VIII sulfonyl groups may be produced by oxidation of the corresponding sulfanyl group using e.g. mCPBA.

Further details for the preparation of the compounds of Formula (I) are found in the examples.

The compounds of Formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000, compounds and more preferably 10 to 100 compounds of Formula (I). Compound libraries may be prepared by a combinatorial "split and mix" approach or by multiple parallel synthesis using either solution or solid phase chemistry, using procedures known to those skilled in the art.

During the synthesis of the compounds of Formula (I), labile functional groups in the intermediate compounds, e.g. hydroxy, oxo, carboxy and amino groups, may be protected. The protecting groups may be removed at any stage in the synthesis of the compounds of Formula (I) or may be present on the final compound of Formula (I). A comprehensive discussion of the ways in which various labile functional groups may be protected and methods for cleaving the resulting protected derivatives is given in, for example, Protective Groups in Organic Chemistry, T.W. Greene and P.G.M. Wuts, (1991) Wiley-Interscience, New York, 2nd edition.

Any novel intermediates as defined above are also included within the scope of the invention. Thus the invention also provides:

a) a compound of formula IV as defined above, wherein R^1 is SO_2R^3 , or $SO_2NR^4R^5$; R^2 is hydrogen;

R^3 is a C_{1-3} alkyl group, a C_{3-7} cycloalkyl group or a 4–6-membered heterocyclic group; R^4 and R^5 are independently hydrogen or C_{1-4} alkyl, provided that R^4 and R^5 are not both hydrogen;

m is 0; and

Δ indicates that the double bond has the (*E*)-configuration; and

b) a compound of formula VIII as defined above, wherein R^1 is SO_2R^3 , or $SO_2NR^4R^5$; R^2 is hydrogen;

R^3 is a C_{3-7} cycloalkyl group or a 4–6-membered heterocyclic group;

R^4 and R^5 are independently hydrogen or C_{1-4} alkyl, provided that R^4 and R^5 are not both hydrogen; and

m is 0.

All publications, including, but not limited to, patents and patent application cited in this specification, are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as fully set forth.

EXAMPLES

Materials and methods:


Column chromatography may be carried out on SiO₂ (40–63 mesh) unless specified otherwise. LCMS data may be obtained employing one of two methods: Method A: Waters Symmetry 3.5μ C₁₈ column (2.1 × 30.0mm, flow rate = 0.8mL/min) eluting with a (5% MeCN in H₂O)–MeCN solution containing 0.1% HCO₂H over 6min and UV detection at 220nm. Gradient information: 0.0–1.2min: 100% (5% MeCN in H₂O); 1.2–3.8min: Ramp up to 10% (5% MeCN in H₂O)–90% MeCN; 3.8–4.4min: Hold at 10% (5% MeCN in H₂O)–90% MeCN; 4.4–5.5min: Ramp up to 100% MeCN; 5.5–6.0min: Return to 100% (5% MeCN in H₂O). Method B: Phenomenex Mercury Luna 3μ C₁₈ column (2.0 × 10.0mm, flow rate = 1.5mL/min), eluting with a (5% MeCN in H₂O)–MeCN solution (4:1 to 1:4) containing 0.1% HCO₂H over 2.95min, & employing diode array detection. The mass spectra for both Methods A and B may be obtained employing an electrospray ionisation source in either the positive (ES⁺) ion or negative ion (ES[−]) mode. Atmospheric Pressure Chemical Ionisation (APCI) spectra may be obtained on a FinniganMat SSQ 7000C instrument.

The synthesis of the following compound has been reported previously:

7(*S*)-iodomethyl-2(*S*),3(*S*)-diphenyl-1,4-dioxaspiro[4,4]nonane: WO2003/095438.

Abbreviations and acronyms: Ac: Acetyl; ATP: Adenosine 5'-triphosphate; *n*-Bu: *n*-Butyl; DMF: *N,N*-Dimethylformamide; DMPU: 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1*H*)-pyrimidinone; DMSO: Dimethylsulfoxide; EDCI: 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; Et: Ethyl; FA: Fold activation; GK: Glucokinase; Glc: Glucose; G6P: Glucose-6-phosphate; G6PDH: Glucose-6-phosphate dehydrogenase; GST-GK: Glutathione *S*-transferase–Glucokinase fusion protein; IH: Isohexane; LHMDs: Lithium bis(trimethylsilyl)amide; Me: Methyl; NADP(H): β-Nicotinamide adenine dinucleotide phosphate (reduced); NBS: *N*-Bromosuccinimide; Ph: Phenyl; rt: room temperature; RT: Retention time; TFAA: Trifluoroacetic anhydride; THF: Tetrahydrofuran.

INTERMEDIATES

Preparation 1: 5-Fluorothiazol-2-ylamine hydrochloride


NEt₃ (63.4mL, 455mmol) was added to a stirred suspension of 5-bromothiazol-2-ylamine hydrobromide (102.7g, 379mmol) in CH₂Cl₂ (1.5L). After 1h, TFAA (64.2mL, 455mmol) was added dropwise at 0°C over 15min. The mixture was allowed to warm to 20°C over 1h, before being stirred for an additional 2h. H₂O (600mL) was added and the resulting precipitate was collected. The aqueous layer of the filtrate was separated and extracted with CHCl₃ (3 × 300mL). The combined organic extracts were washed with brine, dried (Na₂SO₄), filtered and concentrated. The collected precipitate and residual solid were combined and triturated with EtOAc–*n*-C₆H₁₄ to give *N*-(5-bromothiazol-2-yl)-2,2,2-trifluoroacetamide: δ_H (CDCl₃): 7.45 (1H, s), 13.05 (1H, br). *n*-

BuLi (253mL of a 1.58M solution in hexanes, 403mmol) was added dropwise over 50min to a stirred solution of the above amide (50.0g, 183mmol) in anhydrous THF (1.3L) at -78°C . After 1.5h, a solution of *N*-fluorobenzenesulfonimide (86.0g, 275mmol) in anhydrous THF (250mL) was added dropwise over 30min. The mixture was stirred for 3h, before being warmed up to -30°C .

- 5 H₂O (300mL) was added and the mixture was filtered through a Celite pad. The solid collected and Celite were washed with Et₂O (400mL) and H₂O (400mL). The organic layer of the filtrate was separated and extracted with water ($2 \times 400\text{mL}$). The combined aqueous layers were washed with Et₂O (400mL), before being acidified to pH 6.5 with 2M HCl and extracted with EtOAc ($2 \times 400\text{mL}$). The combined organic extracts were washed with H₂O ($2 \times 400\text{mL}$) and brine, before
- 10 being dried (MgSO₄), filtered and concentrated. Column chromatography (EtOAc-*n*-C₆H₁₄, 1:3 to 1:2) gave *N*-(5-fluorothiazol-2-yl)-2,2,2-trifluoroacetamide: δ_{H} (CDCl₃): 7.13 (1H, d). AcCl (12.6mL, 175mmol) was added dropwise to a stirred solution of this amide (15.7g, 73mmol) in MeOH (300mL) at 0°C . The mixture was stirred at 20°C for 30min, heated under reflux for 1h, and finally concentrated *in vacuo*. The residual solid was triturated with THF to give the title compound:
- 15 δ_{H} (D₂O): 7.00 (1H, d).

The free base of the title compound was prepared by suspending the HCl salt in ether, washing with saturated aqueous NaHCO₃, drying the ethereal layer and evaporating to give the free base which was used immediately.

- 20 **Preparation 2:** Ethyl (4-methanesulfonylphenyl)acetate




- SOCl₂ (8.2mL, 112.0mmol) was added to a stirred suspension of (4-methanesulfonylphenyl)acetic acid (20.00g, 93.3mmol) in EtOH (80mL) at -10°C . The mixture was allowed to warm up to 20°C over 16h, then the solvents were removed under reduced pressure. The
- 25 remainder was dissolved in EtOAc and the resulting solution was washed with H₂O until the pH of the aqueous phase was neutral. The EtOAc solution was washed further with saturated aqueous Na₂CO₃, before being dried (MgSO₄). Filtration and solvent evaporation gave the title compound: m/z (ES⁺) = 284.1 [M + MeCN + H]⁺.

- 30 **Preparations 3 - 14:** 2(*R*)-2-(3-chloro-4-methanesulfonylphenyl)-3-((*R*)-3-oxocyclopentyl)propionic acid, 2(*R*)-2-(3-chloro-4-methanesulfonylphenyl)-3-(4-oxocyclohexyl)propionic acid and 2(*R*)-2-(3-chloro-4-methanesulfonylphenyl)-3-(3-hydroxycyclopentyl)propionic acid may be prepared as described in WO2003/095438. The carboxylic acid intermediates of formula VIII required for the synthesis of Examples 7-15 may be
- 35 prepared by the same general procedure, involving alkylation of the appropriate ester with 4-iodomethyl-HC \equiv V followed by hydrolysis of the product.


The carboxylic acid intermediate of formula **VIII** required for the synthesis of Example 7 was prepared as follows:

5 Preparation 6a: (4-Cyclopropylsulfanylphenyl)oxoacetic acid




2M aqueous NaOH (163mL) was added to a solution of ethyl (4-cyclopropylsulfanylphenyl)oxoacetate (40.62g, 162.5mmol) in EtOH (200mL) and the stirred mixture heated at 60°C for 2h. After cooling, the mixture was concentrated to 150mL and washed with ether (2x100mL). Sufficient concentrated HCl was then added to adjust the pH to 1 and the resulting precipitate was extracted into EtOAc (2x300mL). The combined organic phases were washed with water (3x100mL), brine (200mL) and dried (MgSO₄). Removal of the solvent gave the title compound: m/z (ES⁻) = 221.0 [$M - H^+$].

15 Preparation 6b: (4-Cyclopropylsulfanylphenyl)acetic acid



Hydrazine hydrate (14.19g, 283.5mmol) was cooled to -50°C and (4-cyclopropylsulfanylphenyl)oxoacetic acid (**Preparation 6a**, 12.6g, 56.7mmol) added in one portion. The vigorously-stirred slurry was warmed firstly to rt and then at 80°C for 5min. Solid KOH (8.76g, 156.5mmol) was added in four equal portions and the resulting solution heated at 100°C for 20h. On cooling to rt, water (25mL) was added and the aqueous phase washed with Et₂O (20mL). The ethereal phase was itself washed with water (2x15mL) and sufficient concentrated HCl added to the combined aqueous phases to adjust the pH to 1. The resulting precipitate was then extracted into EtOAc (2x300mL) and the combined organic phases washed with water (3x100mL), brine (200mL) then dried (MgSO₄). Evaporation of the solvent gave the title compound: m/z (ES⁻) = 207.1 [$M - H^+$].


Preparation 6c: 2-(4-Cyclopropylsulfanylphenyl)-N-(2(R)-hydroxy-1(R)-methyl-2-phenylethyl)-N-methylacetamide




Anhydrous acetone (148mL) was added to (4-cyclopropylsulfanylphenyl)-acetic acid (**Preparation 6b**, 16.41g, 78.8mmol) and K₂CO₃ (32.67g, 236.4mmol) to form a slurry which was cooled to -10°C with stirring. Neat trimethylacetyl chloride (10.2mL, 82.74mmol) was introduced dropwise, ensuring the temperature did not exceed -10°C during the addition. The reaction mixture

was stirred at -10°C for 20min, warmed to 0°C for 20min then cooled to -15°C and solid (1(*R*),2(*R*))-(-)-pseudoephedrine (19.53g, 118.2mmol) was added in one portion. After 10min, the reaction mixture was brought to rt, where stirring was continued for 1.5h. Water (100mL) was added and the mixture extracted with EtOAc (500mL). The organic phase was washed with water (2x100mL) and the combined aqueous layers back-extracted with EtOAc (2x250mL). The combined organic layers were then washed with brine (100mL) and dried (MgSO₄). The solvent was removed and the solid yellow residue recrystallized from EtOAc-IH to give the title compound: m/z (ES^+) = 356.1 [$M + H$]⁺.

10 **Preparation 6d:** 2(*R*)-(4-Cyclopropylsulfanylphenyl)-3-(3(*R*)-oxocyclopentyl)propionic acid



LHMDS (162mL of a 1M solution in THF, 162mmol) was diluted with anhydrous THF (161mL) and cooled to -20°C with stirring. A solution of 2-(4-cyclopropylsulfanylphenyl)-*N*-(2(*R*)-hydroxy-1(*R*)-methyl-2-phenylethyl)-*N*-methylacetamide (**Preparation 6c**, 30g, 84.4mmol) in anhydrous THF (245mL) was added *via cannula* over 10min, ensuring the reaction temperature remained below -15°C throughout the addition. The reaction was allowed to warm to -7°C over 30min then cooled to -12°C and a solution of 7(*S*)-iodomethyl-2(*S*),3(*S*)-diphenyl-1,4-dioxaspiro[4.4]nonane (27g, 64.2mmol) in a mixture of anhydrous THF (111mL) and DMPU (18.9mL) added *via cannula* over 10min, ensuring the reaction temperature remained below -7°C throughout. The reaction was warmed to 2°C and stirred for 4.5h before being poured into a mixture of toluene (770mL) and 20% aqueous NH₄Cl (550mL). After stirring vigorously, the organic layer was separated and washed with 20% aqueous NH₄Cl (550mL) and brine (100mL). The aqueous phases were combined and extracted with EtOAc (500mL) which, after separation, was washed with brine (100mL). The combined organic phases were dried (MgSO₄), filtered, evaporated and the resulting oil purified by flash chromatography (IH-EtOAc, 9:1 changing incrementally to 1:1) to give 2(*R*)-(4-cyclopropylsulfanylphenyl)-3-(2(*S*),3(*S*)-diphenyl-1,4-dioxaspiro[4.4]non-7(*R*)-yl)-*N*-(2(*R*)-hydroxy-1(*R*)-methyl-2-phenylethyl)-*N*-methylpropionamide: m/z (ES^+) = 648.3 [$M + H$]⁺. A stirred solution of this amide (30.7g, 47.38mmol) in 1,4-dioxane (62mL) was diluted with 4.5M aqueous H₂SO₄ (61.5mL) and the resulting mixture heated under gentle reflux for 18h. After cooling on ice, water (162mL) was added and the mixture extracted with EtOAc (250mL). The aqueous layer was separated and extracted further with EtOAc (2x150mL) and the combined organic phases washed with water (3x200mL), ensuring the final wash was pH neutral, and brine (100mL). After drying (MgSO₄) and filtering, the solvent was removed and the residue purified by flash chromatography (CH₂Cl₂ then CH₂Cl₂-THF, 5:1 changing to 3:1) to give the title compound: m/z (ES^+) = 305.1 [$M + H$]⁺.

Preparation 6c: 2(*R*)-(4-Cyclopropanesulfonylphenyl)-3-(3(*R*)-oxocyclopentyl)propionic acid

A stirred solution of 2(*R*)-(4-cyclopropylsulfonylphenyl)-3-(3(*S*)-oxocyclopentyl)propionic acid (**Preparation 6d**, 5.0g, 16.43mmol) in CH₂Cl₂ (250mL) was cooled to 1°C on ice and 70% *m*CPBA (8.099g, 32.85mmol) added portionwise, maintaining the temperature below 3°C. After 6h the solvent was removed and the residue purified by flash chromatography (1%AcOH in CH₂Cl₂ then THF) to give the title compound: *m/z* (ES⁺) = 337.1 [*M* + H]⁺.

Preparations 15 - 17:

The intermediates of formula IV required for the synthesis of Examples 4-6 may be prepared by the following general processes. Where necessary, any functional groups within the intermediate compounds, e.g. oxo or hydroxy groups in the compounds of formula II, may be protected and the protecting groups removed using conventional means:







Method A: LDA (24mL of a 1.8M solution in *n*-C₇H₁₆-THF-PhEt, 43.3mmol) is added dropwise to a stirred solution of DMPU (19mL, 153.0mmol) in anhydrous THF (100mL) at -78°C. After 30min, a solution of the appropriate phenylacetic ester III (20.6mmol) in anhydrous THF (42mL) is added dropwise. The mixture is stirred further for 1h, before treating dropwise with a solution of aldehyde II or a protected derivative thereof (20.6mmol) in anhydrous THF (25mL). After being allowed to warm up to 20°C over 16h, the reaction is quenched with saturated aqueous NH₄Cl (210mL). The THF is removed under reduced pressure, then the remainder is extracted with EtOAc (3 × 250mL). The combined EtOAc extracts are dried (MgSO₄), filtered, and concentrated. Column chromatography furnishes the acrylate ethyl ester. This ester is saponified, for example, by heating a solution of this ester (19.1mmol) in MeOH (30mL) and 1M NaOH (40mL, 40.0mmol) under reflux for 1h. On cooling, the mixture is washed with EtOAc. The aqueous phase is acidified with 1M HCl, before being extracted with EtOAc. The combined organic extracts are dried (MgSO₄). Filtration and solvent evaporation affords the desired (*E*)-acrylic acid.








Method B: NaOEt (0.63mL of a 0.5M solution in EtOH, 0.32mmol) is added dropwise to a stirred solution of phenylacetic ester III (3.16mmol) and aldehyde II or a protected derivative thereof (3.47mmol) in anhydrous DMSO (3mL). The mixture is heated at 80°C for 16h, before being treated with AcOH to adjust the pH to 7. EtOAc (30mL) is added, then the solution is washed with H₂O (2 × 10mL) and brine (10mL), before being dried (MgSO₄). Filtration, solvent



evaporation, and column chromatography yields the acrylate ethyl ester. This ester is saponified as described above in **Method A** to give the desired (*E*)-acrylic acid.

EXAMPLES

5 The following compounds may be made using the general methods described below:

Example	Structure	Name
1		2(<i>R</i>)-2-(3-Chloro-4-methanesulfonylphenyl)- <i>N</i> -(5-fluorothiazol-2-yl)-3-((<i>R</i>)-3-oxocyclopentyl)propionamide
2		2(<i>R</i>)-2-(3-Chloro-4-methanesulfonylphenyl)- <i>N</i> -(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide
3		2(<i>R</i>)-2-(3-Chloro-4-methanesulfonylphenyl)- <i>N</i> -(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide
4		(<i>E</i>)- <i>N</i> -(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-((<i>S</i>)-3-oxocyclopentyl)acrylamide
5		(<i>E</i>)- <i>N</i> -(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(4-oxocyclohexyl)acrylamide
6		(<i>E</i>)- <i>N</i> -(5-Fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)-2-(4-methanesulfonylphenyl)acrylamide

7		2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide
8		2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide
9		2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide
10		2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-oxocyclopentyl)propionamide
11		2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide
12		2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide
13		2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide

14		2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide
15		2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide

Method C: To a stirred solution of PPh₃ (3.53g, 13.4mmol) in CH₂Cl₂ (70mL) is added NBS (882mg, 10.6mmol) at 0°C. After 10min, the appropriate compound of Formula IV or VIII (9.0mmol) is added, then the mixture is stirred at 0°C for 20 min, and then at 20°C for 30min. 5-Fluorothiazol-2-ylamine hydrochloride (933mg, 9.3mmol) and pyridine (2.2mL, 18.8mmol) are added at 0°C, then the mixture is stirred at 20°C for 20h. After solvent evaporation, the residue is partitioned between 5% aqueous citric acid (100mL) and EtOAc (500mL). The aqueous layer is further extracted with EtOAc (200mL), then the combined organic layers are washed with H₂O and brine, before being dried (Na₂SO₄), filtered, and concentrated in *vacuo*. Chromatographic purification (CHCl₃-MeOH, 99:1) of the residue on Chromatorex[®] NH-DM1020 (Fuji Silysia Chemical, Ltd., Aichi-ken, Japan; see also <http://www.fuji-silysia.co.jp/e-fl100dx.htm>) gives the desired compound.

Method D: EDCI (80mg, 420μmol) and HOBt (56mg, 420μmol) are added to a stirred solution of the appropriate compound of Formula IV or VIII (320μmol) in anhydrous DMF (6mL). After 15min, the solution is treated with 5-fluorothiazol-2-ylamine hydrochloride (38mg, 380μmol) and pyridine (61μL, 760μmol). The mixture is stirred at 20°C for 16h, before being concentrated under reduced pressure. The residue is partitioned between CH₂Cl₂ and saturated aqueous Na₂CO₃. The organic layer is washed with 1M HCl and dried (MgSO₄). Filtration and solvent evaporation gives the desired compound, which, if racemic, can be separated by chiral stationary phase HPLC. Method: CHIRAL CEL OJ[®] (Daicel Chemical Industries, Ltd., Tokyo, Japan), 10cm ø × 25cm, MeOH (100%), 189mL/min, UV 285nm, 25°C.

Method E: Oxalyl chloride (0.23mL, 0.47mmol) is added to a stirred solution of the appropriate compound of Formula IV or VIII (0.42mmol) in anhydrous CH₂Cl₂ (6mL) at 0°C. Anhydrous DMF (50μL) is added, then the mixture is stirred at 0°C for 2h. 5-Fluorothiazol-2-ylamine (151mg, 1.28mmol; obtained by partitioning the hydrochloride salt between Et₂O and saturated aqueous Na₂CO₃, separation of Et₂O layer, drying (MgSO₄), and solvent evaporation) and pyridine (69μL, 0.85mmol) are added, then the mixture is stirred at 0–5°C for 16h, before finally

being allowed to warm to 20°C and diluted with EtOAc (45mL). The solution is washed with 1M HCl (2 × 20mL) and saturated aqueous Na₂CO₃ (2 × 20mL), before being dried (MgSO₄), filtered, and concentrated. Purification via chromatography furnishes the desired compound.

- 5 The compound of **Example 7**, 2(*R*)-2-(4-cyclopropanesulfonylphenyl)-*N*-(5-fluorothiazol-2-yl)-3-((*R*)-3-oxocyclopentyl)propionamide, was prepared as follows:

A solution of 2(*R*)-(4-cyclopropanesulfonylphenyl)-3-(3(*R*)-oxocyclopentyl)propionic acid (**Preparation 6e**, 893mg, 2.65mmol) in anhydrous CH₂Cl₂ (38mL) was cooled to 0°C and a solution of oxalyl chloride (0.408g, 3.21mmol) in anhydrous CH₂Cl₂ (2mL) added dropwise, maintaining the
10 temperature at 0°C during the addition. Dry DMF (0.08mL) was added and the reaction mixture stirred 2.5h. A solution of 2-amino-5-fluorothiazole (**Preparation 1**, 345mg, 2.92mmol) in anhydrous CH₂Cl₂ (6mL) was introduced slowly, followed by pyridine (0.53mL, 5.31mmol) and the mixture stirred at 0°C for 2h then at rt overnight. The solution was diluted with CH₂Cl₂ (150mL) and washed with aqueous 5%w/v citric acid (2x30mL), saturated aqueous NaHCO₃ (2x30mL), water
15 (50mL) and brine (50mL). The organic phase was dried (MgSO₄), evaporated and the residue purified by flash chromatography (IH-EtOAc, 3:2) to afford the title compound: RT = 3.47min; *m/z* (ES⁺) = 437.1 [*M* + H]⁺.

ASSAYS

- 20 In vitro GK activity:

Using a protocol similar to that described in WO2000/58293, GK activity may be assayed by coupling the production of G6P by GST-GK to the generation of NADPH with G6PDH as the coupling enzyme.

The GK assay is performed at 30°C in a flat bottom 96-well assay plate from Costar with a
25 final incubation volume of 100μL. The assay buffer contains: 25mM Hepes buffer (pH 7.4), 12.5mM KCl, 5mM D-Glc, 5mM ATP, 6.25mM NADP, 25mM MgCl₂, 1mM dithiothreitol, test compound or 5% DMSO, 3.0unit/mL G6PDH, and 0.4μL/mL GST-GK, derived from human liver GK. ATP, G6PDH, and NADP may be purchased from Roche Diagnostics. The other reagents are >98% pure and may be purchased from Kanto Chemicals. The test compounds are dissolved in
30 DMSO, before being added to the assay buffer without ATP. This mix is preincubated in the temperature controlled chamber of a SPECTRAmax 250 microplate spectrophotometer (Molecular Devices Corporation, Sunnyvale, CA) for 10min, then the reaction started by the addition of 10μL ATP solution.

After starting the reaction, the increase in optical density (OD) at 340nm is monitored over a
35 10min incubation period as a measure of GK activity. Sufficient GST-GK is added to produce an increase in OD₃₄₀ over the 10min incubation period in wells containing 5% DMSO, but no test compound. Preliminary experiments have established that the GK reaction is linear over this period of time, even in the presence of activators that produced an 8-fold increase in GK activity. The GK

activity in control wells is compared with the activity in wells containing test GK activators. The compound concentrations that produced a 50% increase in GK activity (i.e. FA1.5) are calculated. GK activators achieve FA1.5 at $\leq 30\mu\text{M}$. Using a range of dilutions of the test compound, the maximum increase in GK activity can be calculated along with the concentration of test compound which produces 50% activation (EC_{50}).

The compound of Example 7 achieved greater than 4 fold maximum activation of GK and had an $\text{EC}_{50} < 0.5\mu\text{M}$.


In vivo GK activity:

Following an 18h fasting period, C57BL/6J mice are dosed orally via gavage with GK activator at 50mg/kg body weight. Blood Glc determinations are made 5 times during the 6h post-dose study period.

Mice ($n = 5$) are weighed and fasted for 18h before oral treatment. GK activators are dissolved in the Gelucire vehicle reported in WO 00/58293 (EtOH:Gelucire44/14:PEG400q.s. 4:66:30 v/v/v) at a concentration of 13.3mg/mL. Mice are dosed orally with 7.5mL formulation per kg of body weight to equal a 50mg/kg dose. Immediately prior to dosing, a pre-dose (time zero) blood Glc reading is acquired by snipping off a small portion of the animals' tails ($<1\text{mm}$) and collecting 15 μL blood for analysis. After GK activator treatment, further blood Glc readings are taken at 1, 2, 4, and 6h post-dose from the same tail wound. Results are interpreted by comparing the mean blood Glc values of 5 vehicle treated mice with the 5 GK activator treated mice over the 6h study duration. Compounds are considered active when they exhibit a statistically significant decrease in blood Glc compared to vehicle for 2 consecutive assay time points.

WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

V is $(CH_2)_k$ where one CH_2 group may optionally be replaced by $CH(OH)$, $C=O$, $C=NOH$, $C=NOCH_3$, CHX , CXX^1 , $CH(OCH_3)$, $CH(OCOCH_3)$, $CH(C_{1-4}alkyl)$, or $C(OH)(C_{1-4}alkyl)$;

10 X and X^1 are independently selected from fluoro and chloro;

R^1 and R^2 are independently selected from hydrogen, halogen, hydroxy, amino, cyano, nitro, SR^3 , SOR^3 , SO_2R^3 , $SO_2NR^4R^5$, $NHSO_2R^3$, or a $C_{1-4}alkyl$, $C_{2-4}alkenyl$, $C_{2-4}alkynyl$, $C_{1-4}alkoxy$, or heteroaryl group, wherein any group is optionally substituted with 1 to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, $C_{1-2}alkoxy$, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$, $C_{1-2}alkyl$,
 15 CF_nH_{3-n} , aryl, heteroaryl, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, SCH_3 , $SOCH_3$, SO_2CH_3 , and $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$;

R^3 is a $C_{1-4}alkyl$ group, $C_{3-7}cycloalkyl$ group, aryl group, heteroaryl group, or 4- to 7-membered heterocyclic group, wherein any group is optionally substituted with 1 to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, $C_{1-2}alkoxy$, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$,
 20 $C_{1-2}alkyl$, $C_{3-7}cycloalkyl$, 4- to 7-membered heterocyclic ring, CF_nH_{3-n} , aryl, heteroaryl, $COC_{1-2}alkyl$, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, $SOCH_3$, SO_2CH_3 , and $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$;

R^4 and R^5 are independently hydrogen, or a $C_{1-4}alkyl$ group, $C_{3-7}cycloalkyl$ group, aryl group, heteroaryl group, or 4- to 7-membered heterocyclic group, wherein any group is optionally substituted with 1 to 5 substituents independently selected from halogen, cyano, nitro, hydroxy, $C_{1-2}alkoxy$, $-N(C_{0-2}alkyl)(C_{0-2}alkyl)$, $C_{1-2}alkyl$, $C_{3-7}cycloalkyl$, 4- to 7-membered heterocyclic ring,
 25 CF_nH_{3-n} , aryl, heteroaryl, $-CON(C_{0-2}alkyl)(C_{0-2}alkyl)$, $SOCH_3$, SO_2CH_3 , and $-SO_2N(C_{0-2}alkyl)(C_{0-2}alkyl)$;

or R^4 and R^5 together form a 4- to 8-membered heterocyclic ring which is optionally substituted with 1 or 2 substituents independently selected from $C_{1-2}alkyl$ and hydroxy;

30 k is an integer from 2 to 7;

m is 0 or 1;

n is 1, 2 or 3; and

the dotted line together with the solid line forms an optional double bond, and Δ indicates that the double bond has the (*E*)-configuration.

2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a double bond.
3. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond.
4. A compound according to claim 3, or a pharmaceutically acceptable salt thereof, wherein the dotted line together with the solid line forms a single bond, and the absolute configuration at the asymmetric centre α to the amide carbonyl carbon is (*R*).
5. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein *m* is 0.
6. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein *k* is 4 or 5.
7. A compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein the group formed by --HC< and >V represents 3-oxocyclopentyl, 4-oxocyclohexyl or 3-hydroxycyclopentyl.
8. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 and R^2 are not both hydrogen.
9. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is SOR^3 , SO_2R^3 , or $\text{SO}_2\text{NR}^4\text{R}^5$.
10. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^3 is C_{1-4} alkyl or C_{3-7} cycloalkyl.
11. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is $\text{SO}_2\text{C}_{3-4}$ cycloalkyl.
12. A compound according to any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^2 is hydrogen, chloro, fluoro, or trifluoromethyl.

13. A compound selected from:

2(R)-2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide;

2(R)-2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide;

2(R)-2-(3-Chloro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-((S)-3-oxocyclopentyl)acrylamide;

(E)-N-(5-Fluorothiazol-2-yl)-2-(4-methanesulfonylphenyl)-3-(4-oxocyclohexyl)acrylamide;

(E)-N-(5-Fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)-2-(4-methanesulfonylphenyl)acrylamide;

2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide;

2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide;

2(R)-2-(4-Cyclopropanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-oxocyclopentyl)propionamide;

2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide;

2(R)-2-(4-Cyclobutanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-((R)-3-oxocyclopentyl)propionamide;

2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(4-oxocyclohexyl)propionamide; and

2(R)-2-(3-Fluoro-4-methanesulfonylphenyl)-N-(5-fluorothiazol-2-yl)-3-(3-hydroxycyclopentyl)propionamide;

or a pharmaceutically acceptable salt of any one thereof.

14. A pharmaceutical composition comprising a compound according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

15. A method of prophylactic or therapeutic treatment of a condition where activation of GK is desirable comprising a step of administering an effective amount of a compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt thereof.

16. A method of prophylactic or therapeutic treatment of hyperglycemia or diabetes comprising a step of administering an effective amount of a compound according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof.


5

17. The method according to claim 16 wherein the compound according to any one of claims 1 to 13 is administered in combination with one or more other anti-hyperglycemic agents or anti-diabetic agents.

10 18. A method of prevention of diabetes in a human demonstrating pre-diabetic hyperglycemia or impaired glucose tolerance comprising a step of administering an effective prophylactic amount of a compound according to any of claims 1 to 13, or a pharmaceutically acceptable salt thereof.


19. A process for the preparation of a compound of Formula (Ia):

15




(Ia)

or a pharmaceutically acceptable salt thereof, said process comprising the condensation of a compound of Formula (IV):



(IV)


with a compound of Formula (V):



(V)


25 or a salt thereof, wherein V, R¹, R², m and Δ are as defined in claim 1.

20. A process for the preparation of a compound of Formula (Ib):




(Ib)

said process comprising the condensation of a compound of Formula (VIII):



(VIII)

with a compound of Formula (V):



(V)

or a salt thereof, wherein V, R¹, R² and m are as defined in claim 1.

21. A compound of formula IV as defined in claim 19, wherein R¹ is SO₂R³, or SO₂NR⁴R⁵;
 R² is hydrogen;
 15 R³ is a C₁₋₃alkyl group, a C₃₋₇cycloalkyl group or a 4–6-membered heterocyclic group;
 R⁴ and R⁵ are independently hydrogen or C₁₋₄alkyl, provided that R⁴ and R⁵ are not both
 hydrogen;
 m is 0; and
 Δ indicates that the double bond has the (*E*)-configuration.

22. A compound of formula VIII as defined in claim 20, wherein R¹ is SO₂R³, or SO₂NR⁴R⁵;
 R² is hydrogen;
 R³ is a C₃₋₇cycloalkyl group or a 4–6-membered heterocyclic group;
 R⁴ and R⁵ are independently hydrogen or C₁₋₄alkyl, provided that R⁴ and R⁵ are not both
 25 hydrogen; and
 m is 0.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/050053

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D277/46 A61K31/427 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 03/095438 A (F. HOFFMANN-LA ROCHE AG) 20 November 2003 (2003-11-20) cited in the application examples 25-29, 34, 39-44, 50, 53, 56	1-22
Y	WO 02/08209 A (F. HOFFMANN-LA ROCHE AG) 31 January 2002 (2002-01-31) cited in the application examples	1-22
P, Y	WO 2004/072031 A (OSI PHARMACEUTICALS, INC; FYFE, MATTHEW, COLIN, THOR; GARDNER, LISA, S) 26 August 2004 (2004-08-26) cited in the application examples	1-22
	----- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 July 2005

Date of mailing of the international search report

25/07/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Menegaki, F

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB2005/050053

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01/85706 A (F. HOFFMANN-LA ROCHE AG) 15 November 2001 (2001-11-15) cited in the application page 28 -----	22
X	WO 01/44216 A (F. HOFFMANN-LA ROCHE AG) 21 June 2001 (2001-06-21) cited in the application page 13; examples 3-7,16 -----	21
Y	WO 02/46173 A (F. HOFFMANN-LA ROCHE AG) 13 June 2002 (2002-06-13) examples -----	1-22
Y	US 6 610 846 B1 (BIZZARRO FRED THOMAS ET AL) 26 August 2003 (2003-08-26) examples -----	1-22
Y	WO 00/58293 A (F. HOFFMANN-LA ROCHE AG) 5 October 2000 (2000-10-05) examples -----	1-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2005/050053

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 15-18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/050053

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 03095438	A	20-11-2003	AU 2003232204 A1 BR 0309546 A CA 2482346 A1 WO 03095438 A1 EP 1501815 A1 US 2003225283 A1	11-11-2003 15-02-2005 20-11-2003 20-11-2003 02-02-2005 04-12-2003
WO 0208209	A	31-01-2002	AU 8760001 A BR 0112658 A CA 2416229 A1 CN 1443177 A ,C WO 0208209 A1 EP 1305301 A1 JP 2004504388 T MX PA03000365 A US 2002198200 A1 US 2002042512 A1 ZA 200300173 A	05-02-2002 24-06-2003 31-01-2002 17-09-2003 31-01-2002 02-05-2003 12-02-2004 27-05-2003 26-12-2002 11-04-2002 07-04-2004
WO 2004072031	A	26-08-2004	US 2004181067 A1 WO 2004072031 A2	16-09-2004 26-08-2004
WO 0185706	A	15-11-2001	AT 280163 T AU 778036 B2 AU 6025901 A BR 0110704 A CA 2407759 A1 CN 1427829 A DE 60106599 D1 WO 0185706 A1 EP 1282611 A1 ES 2230309 T3 JP 2003532718 T MX PA02010796 A US 2002002190 A1 ZA 200208367 A	15-11-2004 11-11-2004 20-11-2001 28-01-2003 15-11-2001 02-07-2003 25-11-2004 15-11-2001 12-02-2003 01-05-2005 05-11-2003 27-03-2003 03-01-2002 26-01-2004
WO 0144216	A	21-06-2001	AU 781029 B2 AU 2365201 A CA 2392903 A1 CN 1411453 A ,C CZ 20022412 A3 WO 0144216 A1 EP 1242397 A1 HK 1054383 A1 HR 20020514 A2 HU 0203753 A2 JP 2003516980 T MX PA02005874 A NO 20022863 A NZ 518974 A PL 355815 A1 US 6353111 B1 ZA 200203829 A	28-04-2005 25-06-2001 21-06-2001 16-04-2003 16-10-2002 21-06-2001 25-09-2002 22-04-2005 30-06-2004 28-03-2003 20-05-2003 23-10-2002 14-06-2002 30-04-2004 17-05-2004 05-03-2002 14-08-2003
WO 0246173	A	13-06-2002	AU 2190202 A BR 0115999 A CA 2429642 A1	18-06-2002 30-09-2003 13-06-2002

INTERNATIONAL SEARCH REPORT

Inte al Application No
PCT/GB2005/050053

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0246173	A	CN 1476438 A	18-02-2004
		WO 0246173 A1	13-06-2002
		EP 1341774 A1	10-09-2003
		JP 2004517087 T	10-06-2004
		US 2002111372 A1	15-08-2002
		US 2002103241 A1	01-08-2002
		US 2002103199 A1	01-08-2002
		US 2002107396 A1	08-08-2002
		ZA 200303748 A	16-08-2004
US 6610846	B1 26-08-2003	US 2001039344 A1	08-11-2001
		US 2004014968 A1	22-01-2004
		AT 278680 T	15-10-2004
		AU 767830 B2	27-11-2003
		AU 3963000 A	16-10-2000
		BR 0009486 A	02-01-2002
		CA 2368347 A1	05-10-2000
		CN 1349519 A ,C	15-05-2002
		CZ 20013490 A3	17-04-2002
		DE 60014610 D1	11-11-2004
		WO 0058293 A2	05-10-2000
		EP 1169312 A2	09-01-2002
		ES 2226811 T3	01-04-2005
		HK 1046139 A1	10-12-2004
		HR 20010688 A1	30-06-2003
		HU 0200396 A2	29-07-2002
		JP 2002540196 T	26-11-2002
		MX PA01009814 A	24-04-2002
		NO 20014671 A	26-09-2001
		NZ 514038 A	30-01-2004
		PL 350669 A1	27-01-2003
		RU 2242469 C2	20-12-2004
		SI 1169312 T1	28-02-2005
		TR 200102805 T2	22-04-2002
		US 6528543 B1	04-03-2003
		ZA 200107833 A	23-12-2002
WO 0058293	A 05-10-2000	AT 278680 T	15-10-2004
		AU 767830 B2	27-11-2003
		AU 3963000 A	16-10-2000
		BR 0009486 A	02-01-2002
		CA 2368347 A1	05-10-2000
		CN 1349519 A ,C	15-05-2002
		CZ 20013490 A3	17-04-2002
		DE 60014610 D1	11-11-2004
		WO 0058293 A2	05-10-2000
		EP 1169312 A2	09-01-2002
		ES 2226811 T3	01-04-2005
		HK 1046139 A1	10-12-2004
		HR 20010688 A1	30-06-2003
		HU 0200396 A2	29-07-2002
		JP 2002540196 T	26-11-2002
		MX PA01009814 A	24-04-2002
		NO 20014671 A	26-09-2001
		NZ 514038 A	30-01-2004
		PL 350669 A1	27-01-2003
		RU 2242469 C2	20-12-2004
		SI 1169312 T1	28-02-2005

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2005/050053

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0058293	A	TR 200102805 T2	22-04-2002
		US 2001039344 A1	08-11-2001
		US 6528543 B1	04-03-2003
		US 2004014968 A1	22-01-2004
		US 6610846 B1	26-08-2003
		ZA 200107833 A	23-12-2002
<hr/>			